» Articles » PMID: 32420416

What is the Relationship Between Bone Turnover Markers and Skeletal-related Events in Patients with Bone Metastases from Solid Tumors and in Patients with Multiple Myeloma? A Systematic Review and Meta-regression Analysis

Overview
Journal Bone Rep
Date 2020 May 19
PMID 32420416
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: As a result of the negative impact of bone metastases on patient quality of life, it is important to identify patients at increased risk of skeletal-related events (SREs). Biochemical markers produced by osteoblasts and osteoclasts may provide an early indicator of treatment response to antiresorptive therapy. We aimed to explore the relationship between change in the urinary bone turnover marker cross-linked N-terminal telopeptide of type 1 collagen (uNTX) at the earliest time of steady state and risk of SREs.

Methods: A comprehensive search of eight bibliographic databases and two trial registries was conducted (June 2017). We included randomized controlled trials of adults (≥18 years old) with bone metastases from solid tumors (including breast, lung, prostate) or bone lesions from multiple myeloma that compared denosumab or bisphosphonate(s) with each other or a placebo. Meta-analyses were used to evaluate the relationship between uNTX and SREs. The primary outcomes were based on uNTX at week 13 and SREs in those studies.

Results: Seventeen studies (12,130 patients) were included. The analysis results indicated a positive association between uNTX reduction, measured by the between-group difference of the natural logarithm of the ratio between uNTX at week 13 and baseline, and SRE risk reduction, measured by the natural logarithm of the hazard ratio (HR) for time to first SRE between the two groups (uNTX effect on SRE risk, defined as SRE HR increase corresponding to one unit smaller in the magnitude of uNTX reduction: 0.3560, 95% confidence interval 0.0249-0.6871;  = .0390, R = 0.7360). Results were similar for studies that reported change in uNTX from baseline to week 13 and to later than week 13. The limitation of this review is that it depends on how comprehensive study data were that could be included in the meta-regression.

Conclusions: Our findings support a positive relationship between reduction of bone turnover markers at the earliest time of steady state and reduction in longer-term risk of SREs.

Citing Articles

Assessment of bone turnover markers and DXA parameters to predict bone metastasis progression during zoledronate treatment: a single-center experience.

DOronzo S, Cives M, Lauricella E, Stucci S, Centonza A, Gentile M Clin Exp Med. 2024; 24(1):7.

PMID: 38240866 PMC: 10798926. DOI: 10.1007/s10238-023-01280-1.


Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial.

Li H, Huang Y, Chen Z, Zeng A, Zhang H, Yu Y BioDrugs. 2023; 37(2):259-269.

PMID: 36802320 PMC: 9971153. DOI: 10.1007/s40259-023-00579-5.


The Imbalance of Cytokines and Lower Levels of Tregs in Elderly Male Primary Osteoporosis.

Zhang W, Zhao W, Li W, Geng Q, Zhao R, Yang Y Front Endocrinol (Lausanne). 2022; 13:779264.

PMID: 35721756 PMC: 9205399. DOI: 10.3389/fendo.2022.779264.


Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study "REBUILD".

Terpos E, Ntanasis-Stathopoulos I, Kastritis E, Hatjiharissi E, Katodritou E, Eleutherakis-Papaiakovou E Cancers (Basel). 2022; 14(11).

PMID: 35681747 PMC: 9179322. DOI: 10.3390/cancers14112768.


Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study.

Terpos E, Ntanasis-Stathopoulos I, Katodritou E, Kyrtsonis M, Douka V, Spanoudakis E Cancers (Basel). 2021; 13(6).

PMID: 33809268 PMC: 7998249. DOI: 10.3390/cancers13061257.

References
1.
Saad F, Gleason D, Murray R, Tchekmedyian S, Venner P, Lacombe L . A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94(19):1458-68. DOI: 10.1093/jnci/94.19.1458. View

2.
Coleman R, Brown J, Terpos E, Lipton A, Smith M, Cook R . Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev. 2008; 34(7):629-39. PMC: 3090688. DOI: 10.1016/j.ctrv.2008.05.001. View

3.
Roodman G . Biology of osteoclast activation in cancer. J Clin Oncol. 2001; 19(15):3562-71. DOI: 10.1200/JCO.2001.19.15.3562. View

4.
Yang J, Fizazi K, Peleg S, Sikes C, Raymond A, Jamal N . Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res. 2001; 61(14):5652-9. View

5.
Pockett R, Castellano D, McEwan P, Oglesby A, Barber B, Chung K . The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl). 2009; 19(6):755-60. PMC: 3035821. DOI: 10.1111/j.1365-2354.2009.01135.x. View